TRIM63 and lung cancer: Because not all of the lung cancer patients may benefit from VSV oncolytic viral therapy due to relatively normal function of the IFN pathway in some cancer cells, using IRF-promoter methylation as theranostic method for developing ISG-promoter related biomarkers is capable of assessing the susceptibility of each specific cancer case.